Samuel R. Saks is CEO at JAZZ PHARMACEUTICALS INC (JAZZ). They have made 6 open-market trades across 3 companies since 2007, most recently 2021-02-26.
CIK 0001365615
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $560K since 2007, never a sale. Across 5 scored buys the stock is down 26.4% at ninety days, and 27.9 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 20% | 20% |
| Avg Move | -11.4% | -1.5% | -26.4% |
| Alpha | -8.8% | -3.3% | -27.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TNXP | BUY | 2016-06-21 | 2016-06-21 | $2.00 | $50K | -1.9% | -4.9% | -65.3% |
| TNXP | BUY | 2016-06-21 | 2016-06-29 | $2.00 | $25K | -0.5% | -2.8% | -67.1% |
| TNXP | BUY | 2015-07-17 | 2015-07-17 | $7.50 | $75K | -33.2% | +1.1% | +1.1% |
| ASPX | BUY | 2014-02-10 | 2014-02-12 | $12.00 | $26K | N/A | N/A | N/A |
| JAZZ | BUY | 2007-11-14 | 2007-11-15 | $13.40 | $66K | -10.8% | -0.4% | -0.4% |
| JAZZ | BUY | 2007-11-12 | 2007-11-14 | $13.42 | $318K | -10.8% | -0.4% | -0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.